Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) reported a Q3 non-GAAP diluted loss of $0.02 per share, which is narrower than the Zacks Consensus Estimate of a $0.05 loss. The company's revenue for the quarter was $42.22 million, surpassing the consensus estimate by 0.52%. Despite the revenue beat, Cytek Biosciences has consistently fallen short of EPS estimates in the past four quarters.
Tudor Investment Corp ET AL Invests $867,000 in Cytek Biosciences, Inc. $CTKB
Tudor Investment Corp ET AL has initiated a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB), purchasing 249,812 shares valued at approximately $867,000, now owning 0.20% of the company. Institutional investors collectively hold 69.46% of the stock. Analyst sentiment is mixed with an average "Hold" rating and a target price of $5.38, while the company recently reported a revenue beat but an EPS miss for its latest quarter.
Cytek Biosciences, Inc. (CTKB) Stock Forecasts
The article provides a generic layout for a financial news page, specifically mentioning "Cytek Biosciences, Inc. (CTKB) Stock Forecasts" in its title. However, the content body primarily consists of navigation links, section titles, and various financial and lifestyle categories without any actual article text, stock forecasts, or company-specific information. It appears to be a stub or an error page rather than a complete article.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Consensus Recommendation of "Hold" from Brokerages
Cytek Biosciences (NASDAQ:CTKB) has received a consensus "Hold" rating from six brokerages, with an average one-year target price of $5.38. The company recently reported a quarterly loss, missing EPS estimates, though revenue exceeded expectations. Despite institutional inflows, Cytek remains unprofitable with negative net margin and return on equity.
Vanguard realignment leaves Cytek (NASDAQ: CTKB) ownership at 0 after amendment
The Vanguard Group has reported 0 shares beneficially owned in Cytek Biosciences Inc. (NASDAQ: CTKB) in an amended Schedule 13G/A filing, representing 0% of the class. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries or business divisions began reporting separately. As a result, Vanguard no longer claims beneficial ownership of securities held by these independent entities, indicating a neutral impact and sentiment on Cytek's stock.
CTKB: Sector Recovery And 2026 Guidance Will Support Upside Potential
Analysts have increased the target price for Cytek Biosciences (CTKB) to $5, citing improving sentiment in diagnostic tools and the company's clear multi-year growth framework. Bullish analysts see the updated 2026 guidance as a crucial catalyst for reassessing revenue projections, while bearish outlooks emphasize the reliance on this guidance and ongoing execution risks. The company recently completed a share repurchase program and provided revenue guidance for 2025 and 2026.
Cytek Biosciences outlines $205M–$212M 2026 revenue target amid record Q4 and growth in recurring revenue
Cytek Biosciences has projected a revenue target of $205 million to $212 million for 2026, driven by record fourth-quarter performance and an increase in recurring revenue. The company's growth strategy centers on expanding its product portfolio and market reach, particularly in the flow cytometry sector. This optimistic outlook reflects strong past performance and future expansion plans.
CTKB Stock News Today | Earnings, Events & Price Alerts
This page provides a comprehensive overview of news and events related to CTKB stock (Cytek Biosciences). It highlights recent earnings reports, including record Q4 2025 revenue and a 2025 revenue projection of $201 million, and an analyst's initiation of coverage with an "Equal Weight" rating. The platform aims to offer insights for investors monitoring CTKB.
Cytek Biosciences (CTKB) director converts 6,107 RSUs into common stock
Cytek Biosciences director Richard Chin converted 6,107 Restricted Stock Units (RSUs) into common stock on March 10, 2026, at no exercise price. Following this transaction, Chin directly holds 16,285 shares of common stock and retains 57,004 RSUs. These RSUs represent a contingent right to receive additional shares, vesting on a multi-date schedule.
Cytek Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Cytek Biosciences Inc (CTKB) reported an adjusted loss of 4 cents per share for the quarter ended June 30, beating analysts' mean expectation of a 7-cent loss. Revenue for the quarter fell 2.2% to $45.60 million, missing the expected $46.34 million. Analysts currently rate the stock as "buy" with a median 12-month price target of $5.50.
Topline Capital Management LLC Has $24.10 Million Position in Cytek Biosciences, Inc. $CTKB
Topline Capital Management LLC has significantly increased its stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 32.7%, bringing its total holding to 6,944,280 shares valued at approximately $24.10 million, making CTKB its ninth-largest position. Other institutional investors like Wellington Management Group and Arrowstreet Capital also adjusted their holdings, contributing to a high institutional ownership of 69.46%. Despite missing EPS estimates in its last quarterly report, Cytek Biosciences beat revenue expectations and currently holds an average analyst rating of "Hold" with a $5.50 price target.
Cytek Biosciences (CTKB) CEO awarded options, RSUs and surrenders shares for taxes
Cytek Biosciences President and CEO Wenbin Jiang reported significant equity compensation, including stock options for 485,545 shares and 915,407 restricted stock units (RSUs), both vesting over four years. He also surrendered shares to cover tax obligations arising from previously vested RSUs. Following these transactions, Jiang directly owned 5,422,683 shares of common stock.
Cytek Biosciences (CTKB) CTO granted stock options and 227,535 RSUs
Cytek Biosciences' (CTKB) Chief Technology Officer, Yan Ming, was granted 120,688 employee stock options at an exercise price of $4.23 per share and 227,535 Restricted Stock Units (RSUs) on March 10, 2026. These awards feature four-year vesting schedules. Additionally, Ming exercised previously granted RSUs for 25,400 shares, with 7,731 shares withheld for tax obligations, resulting in his total direct ownership of 6,091,933 common shares.
CTKB - Cytek Biosciences, Inc. Latest Stock News & Market Updates
This page provides news and analysis for Cytek Biosciences (CTKB), a cell analysis solutions company specializing in high-parameter flow cytometry. It compiles updates on the company's financial performance, product innovations like the Aurora™ Evo, and corporate news including partnerships and industry recognition. The archive includes past announcements regarding financial results, product launches, and acquisitions, offering a comprehensive view for investors.
How Cytek’s new Singapore facility speeds cell analysis for Asia’s labs
Cytek Biosciences celebrated the one-year anniversary of its 8,500-square-foot Singapore facility on March 9, 2026, marking a significant milestone in its Asia-Pacific expansion. This hub has enhanced manufacturing capacity, improved supply chain agility, and established a dedicated service and training center, reducing delivery times and strengthening regional engagement. The facility supports global biomedical research by advancing cell analysis solutions and collaborating with local institutions for innovation and talent development.
Cytek Biosciences (CTKB) CLO receives new options, 226,453 RSUs and stock from vesting
Cytek Biosciences' Chief Legal Officer, Valerie Barnett, reported significant equity compensation including a grant of 120,114 stock options and 226,453 restricted stock units (RSUs), both vesting over four years. Additionally, 29,722 previously granted RSUs vested, with 11,748 shares withheld for tax obligations. Following these transactions, Barnett's direct holding of common stock increased to 134,436 shares.
Cytek Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences is celebrating its first anniversary of operations at its Singapore facility, which has significantly enhanced the company's manufacturing capacity, service, and training capabilities across the Asia-Pacific region. This strategic hub has also strengthened global supply chain resilience and helped mitigate geopolitical risks. The facility supports the growing demand for cellular analysis solutions in life sciences research, contributing to scientific discovery and sustained business growth in a rapidly expanding biomedical research market.
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences is celebrating one year of operations at its 8,500-square-foot facility in Singapore, a strategic hub that has significantly enhanced the company's manufacturing capacity, regional service, and training capabilities. This expansion addresses rising demand for cell analysis solutions in the Asia-Pacific (APAC) region and strengthens the global supply chain. The facility supports advancements in life sciences research, contributing to fields like immunology, immuno-oncology, infectious diseases, and cancer drug development.
Cytek Biosciences expands Singapore facility with US$3 million investment
Cytek Biosciences has invested US$3 million to expand its Singapore facility, which serves as a key manufacturing, service, and training center for cell analysis solutions in the Asia-Pacific region. This expansion is part of the company's strategy to enhance its regional operations and supply chain resilience, driven by a 1% year-on-year revenue increase to US$201.5 million in FY2025. The facility supports demand in immunology, infectious diseases, and cancer diagnosis, and Cytek is collaborating with major Singaporean institutions to foster innovation.
CTKB: Sector Recovery And 2026 Guidance Are Expected To Drive Upside
Analyst price targets for Cytek Biosciences (CTKB) have been modestly raised to $6.00, driven by an anticipated recovery in the diagnostic tools sector, higher future P/E assumptions, and clear multi-year growth pathways. Bullish sentiment is fueled by the increased price targets and expectations for positive 2026 guidance, while bearish views note the reliance on future execution and potential sector-wide pullbacks. Cytek Biosciences recently provided 2026 revenue guidance of US$205 million to US$212 million, representing 2% to 5% growth over 2025.
Royce & Associates LP Increases Holdings in Cytek Biosciences, Inc. $CTKB
Royce & Associates LP significantly increased its stake in Cytek Biosciences (NASDAQ:CTKB) by 26.9% in Q3, owning 1,763,262 shares worth approximately $6.12 million. Other institutional investors also raised their positions, bringing the total institutional ownership to about 69.46%. Despite missing EPS estimates but beating revenue, analysts currently rate CTKB as a "Hold" with an average price target of $5.50.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Brokerages
Seven brokerages have issued a consensus "Hold" rating for Cytek Biosciences, Inc. (NASDAQ:CTKB), with an average twelve-month price target of $5.50. Recent analyst actions include downgrades from "strong-buy" to "hold" and reaffirmed "sell" ratings, alongside some reiterated "buy" ratings and price target adjustments. Despite reporting Q4 revenue above consensus and issuing in-line FY2026 guidance, the company posted a significant EPS miss, contributing to downward pressure on the stock.
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) reported a Q4 loss of $0.01 per share, missing the Zacks Consensus Estimate of a $0.02 loss, and representing a -166.67% earnings surprise. However, the company surpassed revenue expectations, posting $62.14 million against an estimate of $62.00 million. Despite topping revenue estimates twice in the last four quarters, CTKB shares have declined by 13.5% year-to-date.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2025 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB) held its Q4 2025 earnings call, reporting a revenue of $62.1 million, an 8% year-over-year increase, meeting expectations despite missing EPS estimates at $-0.3439. The company saw accelerating revenue growth throughout 2025, driven by stabilization in the U.S., a turnaround in the EU, and continued strength in APAC, alongside solid expansion of recurring revenue businesses. Cytek provided a 2026 revenue outlook of $205 million to $212 million, anticipating continued strong growth in service and reagent businesses globally.
Cytek Biosciences (CTKB) Q4 EPS Swing To Loss Reinforces Margin Concerns
Cytek Biosciences reported a Q4 2025 EPS loss of US$0.34, a significant swing from a US$0.07 profit in Q4 2024, despite increased quarterly revenue to US$62.1 million. The company's trailing twelve-month net loss also widened to US$66.5 million. This performance reinforces concerns about margin pressure and profitability, with analysts not expecting the company to be profitable for at least the next three years.
Cytek Biosciences (NASDAQ:CTKB) Announces Quarterly Earnings Results, Misses Estimates By $0.36 EPS
Cytek Biosciences (NASDAQ:CTKB) reported Q4 earnings of ($0.34) per share, missing analyst estimates of $0.02 by $0.36, and posted a 2025 GAAP net loss of $66.5 million. Despite this, the company achieved record quarterly revenue of $62.1 million and full-year revenue of $201.5 million, with recurring revenue showing strong growth. Management provided a 2026 revenue guidance of $205M–$212M and highlighted operational developments, including a new Singapore manufacturing site.
Cytek Biosciences (CTKB) Q4 EPS Swing To Loss Reinforces Margin Concerns
Cytek Biosciences (CTKB) reported a Q4 basic EPS loss of US$0.34 and a net income loss of US$44.1 million, despite higher quarterly revenue of US$62.1 million. This shift from a profit in Q4 2024 to a loss in Q4 2025 emphasizes growing margin pressure and widened trailing losses of US$66.5 million. The company is not expected to be profitable for the next three years, challenging bullish growth narratives centered on recurring revenue and AI tools.
CTKB Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Cytek Biosciences, Inc. (CTKB), including its income statement, balance sheet, and cash flow statement. It highlights key financial metrics for fiscal year 2025, such as revenue of $201.5M, a net income of -$66.5M, and free cash flow of -$8.8M. The company's financial health is assessed as moderate with a score of 46/100, characterized by low profitability, modest revenue growth, strong liquidity, but also weak earnings quality and interest coverage issues.
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Cytek Biosciences reported an 8% increase in fourth-quarter 2025 revenue to $62.1 million, reaching a historical high, and a 1% increase for the full year 2025 to $201.5 million. The company expanded its installed base of instruments and launched new products, including the Cytek Aurora™ Evo system and Cytek® Muse® Micro cell analyzer. Despite revenue growth, net loss for the full year increased significantly to $66.5 million from $6.0 million in 2024, largely due to a non-cash valuation allowance against deferred tax assets and higher operating expenses.
Cytek Biosciences Inc (NASDAQ:CTKB) Reports Q4 2025 Revenue Beat and Mixed Earnings
Cytek Biosciences (NASDAQ:CTKB) reported mixed Q4 2025 financial results, with revenue of $62.14 million significantly beating analyst estimates of $58.33 million, while non-GAAP earnings per share of -$0.01 slightly missed expectations. Despite the EPS miss, investors reacted positively, driving the stock up over 2% in after-hours trading due to the strong revenue performance and a 2026 sales forecast of $211.2 million that aligns with analyst consensus. The company emphasized its continued momentum with its Full Spectrum Profiling (FSP) technology and expanding cell analysis solutions.
Cytek Biosciences, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:CTKB)
Cytek Biosciences, Inc. (CTKB) released its Q4 2025 earnings, reporting an EPS of -$0.29, missing estimates by $0.30, and revenue of $62.14M, which beat by $3.34M, marking an 8.12% year-over-year increase. The company published a slide deck in conjunction with its earnings call.
Cytek (CTKB) Q4 2025 Earnings Call Transcript
Cytek Biosciences (NASDAQ:CTKB) reported Q4 2025 revenue of $62.1 million, an 8% increase year-over-year and a company record, driven by strong growth in EMEA and APAC, and accelerating recurring revenue. Despite a full-year revenue increase of 1% to $201.5 million, the company reported a Q4 net loss of $44.1 million, primarily due to a $38.1 million deferred tax asset valuation allowance and elevated operating expenses, including patent litigation costs. Cytek provided 2026 revenue guidance of $205 million to $212 million, expecting continued growth in services and reagents, and modest instrument sales.
Cytek Biosciences, Inc. (CTKB) Stock Analysis: Exploring a Potential 37% Upside Amid Challenging Valuations
Cytek Biosciences, Inc. (CTKB) is a healthcare company specializing in cell analysis tools, showing a potential upside of 37.30% despite current valuation challenges. The company, which offers products like aurora systems, has a market cap of $558.77 million and serves a global clientele. While facing profitability issues indicated by negative P/E and ROE, Cytek's positive free cash flow and innovative product portfolio suggest potential for future growth, making it an interesting blend of risk and opportunity for investors.
Cytek Biosciences Inc. (CTKB) Stock Falls on Q4 2025 Earnings
Cytek Biosciences Inc. (CTKB) reported Q4 2025 revenue of $62.1 million, surpassing estimates, but experienced a sharp decline in profitability and operating cash flow, leading to a 1.82% stock drop. The company's net loss significantly widened, and diluted EPS missed expectations. Institutional investors showed mixed activity, with some adding and others reducing their stakes, while analysts maintain "Buy" or "Overweight" ratings with a median price target of $6.25.
Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday
Cytek Biosciences (CTKB) is scheduled to announce its Q4 2025 earnings before market open on Thursday, February 26, 2026, with an expected EPS of $0.02. The company, which specializes in cell analysis solutions, currently has a "Hold" consensus rating from analysts with an average price target of $5.50. Institutional investors hold significant stakes in CTKB, with several firms recently increasing their positions.
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
Cytek Biosciences, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference. Management will provide a hybrid presentation and fireside chat on March 4th. A live and archived webcast of the event will be available on the company's investors section.
Live March 4 Cytek Biosciences talk at TD Cowen health care conference
Cytek Biosciences (Nasdaq: CTKB) is scheduled to participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, in Boston. Management will present in a hybrid format and engage in a fireside chat at 8:10 a.m. PT / 11:10 a.m. ET. A live and archived webcast of the presentation will be available on the company's investor relations website.
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Cytek Biosciences, Inc.'s stock (NASDAQ:CTKB) has experienced a 27% decline over the last month, yet its price-to-sales (P/S) ratio of 2.7x remains in line with the Life Sciences industry median. Despite a recent revenue decrease, analysts forecast 7.3% annual revenue growth over the next three years, aligning with industry expectations. This indicates that investors perceive the company's future growth potential to be average, thus justifying its current moderate P/S ratio.
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Cytek Biosciences (NASDAQ:CTKB) has experienced a significant 27% drop in its share price over the last month, contributing to a 20% decline over the past year. Despite this slump, the company's price-to-sales (P/S) ratio of 2.7x remains consistent with the broader U.S. Life Sciences industry average of 2.8x. This alignment suggests that investors' opinions on CTKB's valuation match its industry peers, driven by forecasts of average future revenue growth.
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Cytek Biosciences, Inc. (Nasdaq: CTKB) will announce its financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026. Following the release, the company's management will host a webcast and conference call to discuss the results, business developments, and future outlook. The webcast will be available on the "Investors" section of Cytek's website.
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced it will release its financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026. Following the release, the company will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments, and outlook. The webcast will be accessible on the "Investors" section of Cytek's website.
Cytek Biosciences Stock (CTKB) Opinions on Preliminary Q4 and FY2025 Revenue Results
Cytek Biosciences (CTKB) shares surged following the release of strong preliminary Q4 and full-year 2025 revenue figures, indicating substantial growth across all segments. Social media discussions highlight optimism among traders, with attention now turning to future catalysts for sustained performance. The article also details institutional investor activity, government contracts, and analyst ratings, showing a positive outlook with a median price target of $6.25.
New York State Common Retirement Fund Has $1.15 Million Holdings in Cytek Biosciences, Inc. $CTKB
The New York State Common Retirement Fund significantly reduced its stake in Cytek Biosciences (NASDAQ:CTKB) by 84.1% in Q3, now holding 331,190 shares valued at approximately $1.15 million. Despite this, institutional investors collectively own nearly 69.5% of the company's stock, with various funds recently adjusting their positions. Cytek Biosciences currently has a consensus "Hold" rating from analysts with an average price target of $5.50, and its stock trades around $4.46 with a negative P/E ratio.
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Cytek Biosciences announced preliminary revenue results for Q4 and full year 2025, with total revenue for 2025 expected to be approximately $201 million. Fourth-quarter revenue is projected at about $62 million, an 8% increase over Q4 2024, driven by strong growth in services, reagents, Asia Pacific instrument revenue, and improved instrument sales in the US and EMEA. The company will also present at the 44th Annual J.P. Morgan Healthcare Conference.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Analysts
Cytek Biosciences, Inc. (NASDAQ:CTKB) has received a consensus "Hold" rating from analysts, based on reports from seven research firms. The average one-year price target for the stock is $5.50. The company, which specializes in advanced spectral flow cytometry systems, currently trades at $4.93 with a market capitalization of $630.35 million.
Cytek Biosciences (NASDAQ:CTKB) Trading Up 3.2% - Should You Buy?
Cytek Biosciences (NASDAQ:CTKB) shares increased by 3.2% to $5.16, with trading volume 4% above average. The company specializes in spectral flow cytometry systems for single-cell analysis and has a market cap of approximately $660 million, with institutional ownership at nearly 69.5%. Analyst ratings are mixed, leading to an average "Hold" rating and a consensus price target of $5.50.
Cytek Biosciences Data Breach Investigation
Strauss Borrelli PLLC is investigating a data breach at Cytek Biosciences, Inc. that exposed sensitive personal and protected health information. The breach, which occurred around November 1, 2025, involved unauthorized access to Cytek's systems, leading to potential compromise of data including names, Social Security numbers, contact information, and health details. Cytek began notifying impacted individuals on December 22, 2025, and is offering 24 months of complimentary credit monitoring services.
Institutional owners may take dramatic actions as Cytek Biosciences, Inc.'s (NASDAQ:CTKB) recent 6.9% drop adds to one-year losses
Institutional investors hold a significant 52% stake in Cytek Biosciences, Inc. (NASDAQ:CTKB), making them influential in the company's stock performance. A recent 6.9% drop, contributing to a 1.1% one-year loss for stockholders, could lead these institutions to sell, potentially impacting individual investors. BlackRock, Inc. is the largest shareholder, and the top 10 shareholders control over half the company, while insiders own shares worth US$64 million.
Institutional owners may take dramatic actions as Cytek Biosciences, Inc.'s (NASDAQ:CTKB) recent 6.9% drop adds to one-year losses
Institutional investors own 52% of Cytek Biosciences (NASDAQ:CTKB), making them a powerful force in the company's stock performance. A recent 6.9% stock drop added to a 1.1% one-year loss, which could lead institutions to sell shares, impacting individual investors. The top 10 shareholders hold 50% of the business, with BlackRock, Inc. being the largest at 13%.
Cytek Biosciences Debuts Optimized Immunoprofiling Kit
Cytek Biosciences has introduced a new 14-color immunoprofiling kit designed to simplify and accelerate the process of profiling the human immune system. This kit features optimized cFluor reagents chosen by Cytek's scientists to work effectively in multicolor panels, making data analysis easier and reducing variability. The solution aims to streamline complex multicolor panel optimization for researchers studying immunology and cellular functions.
